Cognito Therapeutics and Ochsner Health just launched a new initiative. They call it the Brain Health Collaboratory. This partnership focuses on advancing Alzheimer’s Care Models through innovation. It serves patients across Louisiana, Mississippi, and the Gulf South. The collaboratory uses Cognito’s investigational Spectris technology. This platform explores new ways to deliver brain health care. It targets both urban and rural communities in the region. Furthermore, Ochsner will integrate this technology into its clinical network.
A new state-of-the-art facility will open in New Orleans in late 2026. This center will house Ochsner’s renowned neuroscience programs. Consequently, patients will receive a seamless and centered experience.
“This new collaboratory affords us the opportunity to pair emerging neurotechnology with real-world clinical care to better understand how we can slow cognitive decline, improve patients’ lives and open new therapeutic pathways for other neurological diseases in the future,” said David Houghton, MD, system chair of neurology, Ochsner Health.
The partners will also develop a Brain Health Index. This framework tracks disease progression and treatment response. Moreover, they want to refine Alzheimer’s Care Models for high-risk populations. This includes patients using Medicare and Medicaid.
“Ochsner’s reach across the Gulf South provides a unique opportunity to bring innovative brain health technologies to a broad patient population,” said Christian Howell, chief executive officer of Cognito Therapeutics. “Partnerships like this are essential to ensuring that new therapies can reach patients not just in major academic centers, but across entire healthcare systems that serve both urban and rural communities. Expanding access to patients is critical to generating real-world evidence and ultimately delivering new options for people living with Alzheimer’s disease.”
“We are proud to partner with Cognito Therapeutics and advance this groundbreaking brain health initiative in the Gulf South,” said Pete November, president and chief executive officer, Ochsner Health. “Partnerships like this are only possible because of the extraordinary talent and dedication of our physicians, advanced practice providers, nurses, and support and administrative teams across neurosciences. Additionally, the unwavering support of Bobby and Debbie Patrick, along with other generous donors, have made our soon-to-be open neuroscience institute a reality. Together, we are building a future where innovation and compassionate care come together to transform lives.”
The Spectris device uses light and sound stimulation. It aims to promote healthy neural activity at home. Meanwhile, researchers continue to evaluate the device in clinical trials. This collaboration builds on a successful 2025 pilot in West Virginia. Finally, this effort strengthens the region’s commitment to effective Alzheimer’s Care Models.
“True medical excellence comes from combining expert, compassionate care with the most advanced technology available. By integrating breakthrough innovation into daily practice, Ochsner is building a proactive future for brain health. The Debra H. And Robert J. Patrick Neuroscience Institute will be a place where technology and expert medical treatment meet in one state-of-the-art facility, ensuring the highest standard of care for our communities. My family and I are excited for what’s to come,” said Bobby Patrick, New Orleans businessman, entrepreneur and managing partner, Patrick Family Foundation.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
